- HMS Community Values
- Introduction to Clinical Research Training
- Medical Education
- Dean for Medical Education
- Financial Aid
- Student Services
- MD Programs
- Student Handbook
- Being a Student at Harvard Medical School
- History of Harvard Medicine
- 1. The MD Programs at Harvard Medical School
- 2. Academic Information and Policies
- 2.01 Academic Calendars
- 2.02 Attendance
- 2.03 Grading and Examination
- 2.04 Adding or Dropping Courses
- 2.05 Cross Registration
- 2.06 Licensure: USMLE (United States Medical Licensing Examination)
- 2.07 Full or Part-time Status Requirements
- 2.08 Policy on Length of Time to Complete Degree
- 2.09 Leaves of Absence
- 2.10 Withdrawal
- 2.11 Readmission
- 2.12 Credit for Work Done Prior to Matriculation
- 2.13 Credit for Special Programs or Extramural Work (i.e., away rotations)
- 2.14 Rules Governing Other Educational Experiences
- 2.15 Transcripts and Enrollment Confirmation Statements
- 2.16 Access to Educational Records
- 2.17 Advanced Standing Students
- 2.18 Curriculum Continuity: Policy on Interruption
- 2.19 Satisfactory Academic Progress
- 2.20 Student Workload and Duty Hours on Core and Elective Clinical Rotations
- 2.21 Pregnancy and Childbirth during Medical School
- 2.22 Medical Student Performance Evaluation (MSPE) - Dean's Letter
- 3. Academic Resources
- 4. Student Conduct and Responsibility
- 5. Combined degree programs
- 6. Financial Obligations
- 7. General Policies
- 8. Housing and Dining Services
- 9. Student Health
- 10. Services and Programs
- Education Matters
- Student Profiles
- Curriculum Services
- The Academy at Harvard Medical School
- Program Evaluation and Student Assessment
- Anatomical Gift Program
- Contact Us
- Teaching Awards
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- The Academy
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- Cancer Biology & Therapeutics Program
- Celiac Program
- Department of Medicine
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Big Data In Healthcare
- Institutional Planning and Policy
- Master of Medical Sciences In Clinical Investigation
- Office of Global Education
- Portugal Clinical Scholars Research Training Program
- Safety Quality Informatics and Leadership
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Human Resources
- Jobs @ HMS
- Dental Medicine
- Harvard University
- Contact us
The Cell that Caused Melanoma
A team led by Harvard Medical School researchers at Boston Children’s Hospital has, for the first time, visualized the origins of cancer from the first affected cell and watched its spread in a live animal.
The researchers’ work, published in the Jan. 29 issue of Science, could change the way scientists understand melanoma and other cancers and could one day lead to new, early treatments before the cancer has taken hold.
“An important mystery has been why some cells in the body already have mutations seen in cancer but do not yet fully behave like the cancer,” said the paper’s first author, Charles Kaufman, HMS instructor in medicine at Dana-Farber Cancer Institute and a postdoctoral fellow in the Zon Laboratory at Boston Children’s Hospital.
“We found that the beginning of cancer occurs after activation of an oncogene or loss of a tumor suppressor and involves a change that takes a single cell back to a stem cell state,” said Kaufman.
That change, Kaufman and colleagues found, involves a set of genes that could be targeted to stop cancer from ever starting.
The study imaged live zebrafish over time to track the development of melanoma.
All the fish had the human cancer mutation BRAFV600E, found in most benign moles, and also had lost the tumor suppressor gene p53.
Kaufman and colleagues engineered the fish so that individual cells would light up in fluorescent green if a gene called crestin was turned on—a “beacon” indicating activation of a genetic program characteristic of stem cells. This program normally shuts off after embryonic development, but occasionally, for reasons not yet known, crestin and other genes in the program turn back on in certain cells.
“Every so often we would see a green spot on a fish,” said the study’s senior investigator, Leonard Zon, professor of stem cell and regenerative biology in the Faculty of Arts and Sciences at Harvard University and director of the Stem Cell Program at Boston Children’s. “When we followed them, they became tumors 100 percent of the time.”
Caught in action
When Kaufman, Zon and colleagues looked to see what was different about these early cancer cells, they found that crestin and the other activated genes were the same ones turned on during zebrafish embryonic development—specifically, in the stem cells that give rise to the pigment cells known as melanocytes, within a structure called the neural crest.
“What’s cool about this group of genes is that they also get turned on in human melanoma,” said Zon. “It’s a change in cell fate, back to neural crest status.”
Finding these cancer-originating cells was tedious. Wearing goggles and using a microscope with a fluorescent filter, Kaufman examined the fish as they swam around, shooting video with his mobile phone. Scanning 50 fish could take two to three hours.
In 30 fish, Kaufman spotted a small cluster of green-glowing cells about the size of the head of a Sharpie marker. In all 30 cases, these grew into melanomas. In two cases, he was able to see a single green-glowing cell and watch it divide and ultimately become a tumor mass.
“It’s estimated that only one in tens or hundreds of millions of cells in a mole eventually become a melanoma,” said Kaufman. “Because we can also efficiently breed many fish, we can look for these very rare events. The rarity is very similar in both humans and fish, which suggests that the underlying process of melanoma formation is probably much the same in humans.”
Zon and Kaufman believe that their findings could lead to a new genetic test for suspicious moles to see whether the cells are behaving like neural crest cells, indicating that the stem cell program has been turned on.
They are also investigating the regulatory elements that turn on the genetic program, known as super-enhancers. These DNA elements have epigenetic functions that are similar in zebrafish and human melanoma and could potentially be targeted with drugs to stop a mole from becoming cancerous.
A paradigm shift for cancer?
Zon and Kaufman posit a new model for cancer formation, going back to a decades-old concept called field cancerization. They propose that normal tissue becomes primed for cancer when oncogenes are activated and tumor suppressor genes are silenced or lost, but that cancer develops only when a cell in the tissue reverts to a more primitive, embryonic state and starts dividing. They believe this model may apply to most—if not all—cancers, not just melanoma.
The study was supported by the National Cancer Institute (R01 CA103846) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08 AR061071) of the National Institutes of Health, the Ellison Foundation, the Melanoma Research Alliance, the V Foundation for Cancer Research and the Howard Hughes Medical Institute. Leonard Zon is a co-founder and stockholder of Fate Therapeutics and Scholar Rock.
Adapted from a Boston Children’s news release.
Stay informed via email on the latest news, research, and
media from Harvard Medical School.